Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial.

Overview of attention for article published in Cancer Prevention Research, June 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 2 X users, with an upper bound of 2,264 followers.

#ICYMI— Targeting the Leukotriene Pathway for #ColonCancer Interception, by Mohammed et al. https://t.co/Y2uHifEaC3

Reply Repost Favourite

#ICYMI— Leukotriene Receptor Antagonist Therapy for the #Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial, by Higurashi et al. https://t.co/TV4jvmRBrh @YCU_koho https://t.co/6zPeNOg3BM

Reply Repost Favourite

In the Spotlight— Targeting the Leukotriene Pathway for #ColonCancer Interception, by Mohammed et al. https://t.co/Y2uHifVdE3

Reply Repost Favourite

From the October issue— Leukotriene Receptor Antagonist Therapy for the #Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial, by Higurashi et al. https://t.co/dF2bgJcvmI @YCU_koho https://t.co/Low7o4KDFF

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.